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Meta-analysis of Randomized Trials Comparing Carotid
Endarterectomy and Endovascular Treatment
T. Luebke,* M. Aleksic and J. Brunkwall
Division of Vascular Surgery, University of Cologne, Cologne, Germany
Objective and design. In order to evaluate the comparative efficacy and safety of carotid angioplasty with or without stent
placement (CAS) versus carotid endarterectomy (CEA) we performed a meta-analysis of the presently available randomized
studies.
Materials and methods. A multiple electronic health database search on all randomized trials describing CAS compared
with CEA in patients with symptomatic or asymptomatic carotid artery stenosis was performed.
Results. Seven trials totalling 2972 patients (1480 randomized to CEA and 1492 randomized to CAS) were included in
the meta-analysis. Results significantly favoured CEA over CAS in terms of death or any stroke at 30 days after procedure;
the risk of death, any stroke, or myocardial infarction at 30 days; ipsilateral ischaemic stroke at 30 days; any stroke at 30
days; death or stroke at 6 months; and the risk of procedural failure.
There was a significantly reduced risk of cranial neuropathy at 30 days after CAS. There was no significant difference be-
tween CAS and CEA groups in the odds of death or disabling stroke at 30 days, death or stroke at 1 year after the procedure,
and ipsilateral intracerebral bleeding at 30 days.
Conclusions. The results of this meta-analysis suggest that CEA can be performed with more safety than CAS. As a result,
CEA remains the ‘‘gold standard’’ treatment for suitable de novo carotid stenosis and CAS should only be performed within
randomized trials of stenting versus surgery.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Carotid angioplastywith stenting (CAS) is increasingly
used in the treatment of extracranial carotid athero-
sclerosis.1e14 In order to supersede carotid endarterec-
tomy as the standard treatment for carotid stenosis,
CAS must be shown to be at least as safe and effective
as surgery. However, the exact role of CAS in the treat-
ment of carotid stenosis, and the long-term efficacy of
this technique is not yet defined.
A systematic review15 of five randomized trials
comparing stenting with endarterectomy16e21 con-
cluded that ‘‘there is currently insufficient evidence
to support a widespread change in clinical practice
away from recommended CEA as the treatment of
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the results of two further trials were published, namely
Stent-Supported Percutaneous Angioplasty of the
Carotid Artery versus Endarterectomy trial (SPACE),22
and Endarterectomy versus Angioplasty in patients
with Severe Symptomatic Stenosis (EVA-3S).23 At the
moment, two more trials are ongoing in Europe24 and
the United States.25
The objective of this study was to carry out a meta-
analysis of all randomized trials of CAS compared
with CEA in patients with carotid stenosis suitable
for surgery.
Materials and Methods
Study selection
A multiple electronic health database search was per-
formed including Medline, Embase, Ovid, Cochranelar Surgery. Published by Elsevier Ltd. All rights reserved.
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base of Abstracts of Reviews of Effectiveness (DARE),
on all randomized trials published between 1966 and
December 2006 describing CAS compared with CEA.
These databases were searched with an unrestricted
search strategy, using exploded MeSH (medical sub-
ject heading) terms (carotid arteries, stenosis, endovas-
cular, stents, angioplasty, endarterectomy, stroke, and
cerebrovascular disease).
Outcome measures
The tables and outcome definitions used were devel-
oped a priori by the investigation team, namely any
stroke (disabling or non-disabling) or death within
30 days of the procedure, subsequent ipsilateral ca-
rotid territory stroke, subsequent stroke in any arterial
territory, cranial neuropathy within 30 days of the
procedure, other complications of the procedure, eg.
myocardial infarction and restenosis rate.
Inclusion criteria
We included randomized trials (RCTs) of carotid
endovascular treatment compared with carotid endar-
terectomy in patients of any age or sex with symptom-
atic or asymptomatic carotid artery stenosis who
had either bilateral or unilateral procedures. Each trial
was critically appraised by all investigators, using
a critical review checklist for study validity as
proposed by the Dutch Cochrane Collaboration,
Dutch Cochrane Centre, Therapy checklist (Dutch
extended version) (http://www.cochrane.nl., [acces-
sed May 2005]).26
Exclusion criteria
Non-randomized prospective trials, retrospective
studies, controlled clinical trials, comparative ob-
servational studies, non-comparative observational
studies, case series studies and population-based
registries comparing CAS with CEA or that did not
include a randomized comparison with CEA were
excluded.
Quality of trials
T.L. and M.A. independently assessed the methodo-
logical quality of included trials using the checklist
recommended by the Cochrane PVD Review Group.
J.B. resolved any disagreements. The assessment ofstudy quality was based on the methods described
by Jadad.27
Statistical analysis
Statistical analysis for categorical variables was car-
ried out using odds ratios (ORs) as the summary sta-
tistic. An OR of less than 1 favours the CAS group,
and the point estimate of the OR is considered statis-
tically significant at the P < 0.050 level if the 95 per
cent confidence interval (c.i.) does not include the
value 1. To combine the OR for the outcomes of inter-
est a Peto fixed-effects technique was used. Yates’ cor-
rection was used for those studies that contained
a zero in one cell for the number of events of interest
in one of the two groups.28,29
Two strategies were used to assess heterogeneity
quantitatively. First, data were reanalysed using
both random- and fixed-effects models. Second,
graphical exploration with funnel plots for asymme-
try was performed.
Analysis was conducted using the statistical soft-
ware Statistical Package for Social Sciences (SPSS
12.0, Chicago, IL, USA) for Windows and Review
Manager Version 4.2 (The Cochrane Collaboration,
Update Software, Oxford, UK).
Results
Studies selected
The electronic literature search yielded 16 papers that
were retrieved for full text appraisal; of these, 7 ran-
domized studies17e23,30 fulfilled all inclusion criteria,
and were included in the meta-analysis (Table 1). A
total of 2972 patients (1480 randomized to CEA and
1492 randomized to CAS) were analyzed. Four of
the seven studies included only patients with symp-
tomatic carotid stenosis. Three trials (CAVATAS,
Kentucky, SAPPHIRE) analyzed patients with symp-
tomatic and asymptomatic stenosis. One trial (SAP-
PHIRE) included only patients considered at high
surgical risk for CEA.
In the latter three of the seven trials (SPACE, EVA-
3S, SAPPHIRE) a distal protection device was used ei-
ther in all CAS patients or a part thereof. The rate of
successful deployment of the stent ranged from 89%
to 100%. In all studies, an additional stent was used
after primary angioplasty. Blinding of health workers,
patients, and assessors to treatment or outcome was
not feasible because of study design and the nature
of the interventions.
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474 T. Luebke et al.Assessment of functional outcome
No uniform assessment of the neurological status was
performed in the various trials. In the Leicester study
functional outcome was assessed by the Oxford
Handicap Stroke score. In Kentucky A, Kentucky B,
Wallstent, and SAPPHIRE a combination of the Bar-
thel, Rankin, and National Institutes of Health Stroke
Scale scores was used, the so called >1 scale to mea-
sure outcome. In CAVATAS, stroke outcome events
were classified as fatal if death occurred as a direct
result of stroke at any time after the event, or as
disabling if survivors required help from another per-
son as a result of stroke to undertake everyday activ-
ities for >30 days after the onset of symptoms
(equivalent to modified Rankin grade 3 or worse).
The remainder of stroke outcome events were classi-
fied as nondisabling if symptoms lasted >7 days.
In EVA-3S, the degree of disability from stroke and
functional disability from cranial-nerve injury was as-
sessed by the study neurologist. In SPACE, stroke out-
come was assessed by independent neurologists.
Disabling ipsilateral stroke was defined by a score
on the modified Rankin scale of at least 3.
Restenosis rates
CAVATAS was the only study that explicitly reported
restenosis rates. In that study, ipsilateral stenosis of
>70% 1 year after treatment was more common after
CAS than CEA (14% compared with 4%; P< 0.001),
where the low rate of stent use has to be considered.
Meta-analysis
Intention-to-treat analysis could be performed on all
trials (Figs. 1ae2a). The rates of the major outcomes
for each of the included studies are depicted in Table 2.
Results significantly favoured CEA over CAS for
death or any stroke at 30 days after the procedure
(OR 1.39 (95 per cent c.i. 1.05 to 1.84)), ipsilateral is-
chaemic stroke at 30 days after the procedure (OR
1.48 (95 per cent c.i. 1.05 to 2.07)), any stroke at 30
days after the procedure (OR 1.50 (95 per cent c.i.
1.05 to 2.16)), death or stroke at 6 months after the pro-
cedure (OR 1.99 (95 per cent c.i. 1.09 to 3.62)), and the
risk of procedural failure (OR 3.42 (95 per cent c.i. 2.03
to 5.79)).
There was, however, a significantly reduced risk of
cranial neuropathy at 30 days after the procedure for
CAS (OR 0.15 (95 per cent c.i. 0.09 to 0.26)).
There was no significant difference between CAS
and CEA groups in the odds of death or stroke at 1
Eur J Vasc Endovasc Surg Vol 34, October 2007year after the procedure (OR 1.01 (95 per cent c.i.
0.71 to 1.44)) or ipsilateral intracerebral bleeding at
30 days after the procedure (OR 0.57 (95 per cent c.i.
0.17 to 1.87)).
Publication bias
To test whether publication bias was present within
the above sample included in the meta-analysis, a fun-
nel plot was undertaken. (Figs. 1be2b). None of the
studies lies outside the limits of the 95 per cent c.i.
The funnel plot shows no publication bias, all studies
being equally distributed around the vertical axis.
Sensitivity analysis
Weperformed sensitivity analysis to test the results un-
der varied conditions such as the exclusion of trials that
contributed the most number of patients. After exclu-
sion of SPACEorCAVATAS the results remained signif-
icant; however, after exclusion of EVA-3S or all three
studies the Peto odds ratios for the effect size showed
no significant difference between CAS and CEA.
In three of the seven studies included cerebral pro-
tection devices were used. After exclusion of these tri-
als, the sensitivity analysis could not demonstrate any
significant difference concerning the Peto odds ratio
for CAS versus CEA. A subgroup analysis only for pa-
tients with symptomatic carotid stenosis still demon-
strated significant differences of composite rates of
stroke or death among patients in the CAS group
compared with the CEA group.
Using a random-effects model instead of a fixed-
effects model, evaluating the Peto odds ratios during
sensitivity between CAS and CEA a nonsignificant
difference of relative risk for 30-day rates of stroke
and death was observed (P¼ 0.14). For sensitivity
analysis, evaluation of the relative risk difference for
the effect size of all studies a fixed-effects model
was also applied. The fixed-effects model recorded a
significant increase of 30-day rates of stroke or death
(P¼ 0.02) (Table 3).
Discussion
Nonrandomized experience originating from over
5000 carotid angioplasty and stenting procedures for
carotid stenosis in high-risk and even in patients with-
out increased surgical risk2e14,31 suggested, that CAS
would be associated with acceptable periprocedural
complication rates as the 30-day risk of stroke or
death ranged from 2% to 9%, with an average rate
475Meta-analysis of Carotid Stenting Versus SurgeryReview: Carotid endarterectomy versus carotid stent
Comparison: 01 carotid endarterectomy versus carotid stent
Outcome: 01 30-day death or stroke
Study Treatment Control Peto OR Weight Peto OR
or sub-category n/N n/N 95% CI % 95% CI Quality
Leicester / Naylor        5/11               0/12   2.13     12.88 [1.85, 89.61]       A
CAVATAS       25/251             25/253  23.51      1.01 [0.56, 1.81]        A
Kentucky A / Brooks        0/53               1/51   0.52      0.13 [0.00, 6.56]        B
Wallstent       13/107              5/112   8.64      2.76 [1.05, 7.22]        A
Kentucky B / Brooks        0/43               0/42        Not estimable B
SAPPHIRE / Yadav        6/167              9/167   7.49      0.66 [0.23, 1.85]        A
EVA-3S / Mas       25/261             10/259  17.04      2.48 [1.25, 4.93]        A
SPACE       46/599             38/584  40.68      1.19 [0.77, 1.86]        A
Total (95% CI) 1492 100.00      1.39 [1.05, 1.84]
Total events: 120 (Treatment), 88 (Control)
Test for heterogeneity: Chi² = 14.77, df = 6 (P = 0.02), I² = 59.4%
Test for overall effect: Z = 2.28 (P = 0.02)
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Fig. 1. a. The effect of endovascular treatment versus endarterectomy for patients with carotid artery stenosis on the com-
bined outcome ‘‘death or any stroke within 30 days of procedure’’. Results are expressed as Peto odds ratio (OR) with a fixed
effects model. OR <1 suggests endovascular treatment to be superior to endarterectomy. b. Assessment of publication bias
using a funnel plot: No asymmetry is observed in the plot.of 4.7%. An essential shortcoming of the CAS case se-
ries mentioned above is their non-randomized study
design with the potential risk of bias due to heteroge-
neity of patient selection and severety of the lesions.
Furthermore, outcome was assessed by independent
neurologists or physicians in very few studies (see
Table 1). Thus randomised controlled trials were re-
quired to assess the outcome of carotid stenting by
comparison to endarterectomy.32,33
A recent meta-analysis15 of five prospective ran-
domized trials comparing stenting with endarter-
ectomy16e20,34 by analyzing a total of 1269 patientsdemonstrated a 30-day odds of stroke or death after
CAS of the carotid artery of 8.1% (51 of 632 patients;
range, 0.0 to 12.1%), and for CEA a 30-day odds of
death or any stroke of 6.3% (40 of 637 patients; range,
0.0 to 9.9%). However, the difference between the two
treatments was not statistically significant. On the ba-
sis of the bottom-line conclusion of this meta-analysis,
the authors stated that there was no evidence to sup-
port a shift from the recommendation of CEA as the
standard treatment for carotid stenosis.15e20,34 On
the contrary, this meta-analysis only offers Phase I-
type evidence that CAS can be performed relatively
Eur J Vasc Endovasc Surg Vol 34, October 2007
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Comparison: 01 carotid endarterectomy versus carotid stent
Outcome: 03 1-year death or stroke
Study  Treatment Control Peto OR  Weight  Peto OR
or sub-category n/N n/N 95% CI % 95% CI Quality
 CAVATAS       36/251             34/253  49.42      1.08 [0.65, 1.79] A
 Wallstent       13/107              4/112  12.88      3.30 [1.23, 8.85] A
 SAPPHIRE / Yadav       22/167             33/167  37.70      0.62 [0.35, 1.11] A
Total (95% CI) 525                532 100.00      1.01 [0.71, 1.44]
Total events: 71 (Treatment), 71 (Control)
Test for heterogeneity: Chi² = 8.31, df = 2 (P = 0.02), I² = 75.9%
Test for overall effect: Z = 0.06 (P = 0.95)
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Review: Carotid endarterectomy versus carotid stent
Comparison: 01 carotid endarterectomy versus carotid stent
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Fig. 2. a. The effect of endovascular treatment versus endarterectomy for patients with carotid artery stenosis on the com-
bined outcome ‘‘death or any stroke at 1 year’’. Results are expressed as Peto odds ratio (OR) with a fixed effects model. OR
<1 suggests endovascular treatment to be superior to endarterectomy. b. Assessment of publication bias using a funnel plot:
No asymmetry is observed in the plot.
Table 2. Rates of outcome events in the individual trial
Study 30-Day Death or
Stroke
30-Day Death or
Disabling Stroke
1-Year Death or
Stroke
30-Day Cranial Nerve
Injury
Endovasc
No. (%)
Surgery
No. (%)
Endovasc
No. (%)
Surgery
No. (%)
Endovasc
No. (%)
Surgery
No. (%)
Endovasc
No. (%)
Surgery
No. (%)
CAVATAS 25 (10) 25 (9.9) 16 (6.4) 15 (5.9) 36 (14.3) 34 (13.4) 0 (0) 22 (8.7)
Kentucky A 0 (0) 1 (2) 0 (0) 1 (2) NK NK 0 (0) 4 (7.8)
Kentucky B 0 (0) 0 (0) 0 (0) 0 (0) NK NK 0 (0) 0 (0)
Leicester 5 (45.5) 0 (0) 3 (27.3) 0 (0) NK NK 0 (0) 0 (0)
WALLSTENT 13 (12.1) 5 (4.5) NK NK 13 (12.1) 4 (3.6) NK NK
SAPPHIRE 8 (4.8) 9 (5.4) NK NK 22 (13.2) 33 (19.8) 0 (0) 8 (4.8)
SPACE 46 (7.7) 38 (6.5) 28 (4.7) 22 (3.8) NK NK NK NK
EVA-3S 25 (9.6) 10 (3.9) 9 (3.4) 4 (1.5) 31 (11.7)
6 months
16 (6.1)
6 months
3 (1.1) 22 (7.7)
Values are numbers or percentage (%) of patients.
MI indicates myocardial infarction; NK, not known.
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Fixed-
effects
model,
Peto odds
ratio
Random-effects
model,
Peto odds
ratio
Fixed-effects
model,
relative risk
Exclusion of
large trials
Exclusion of trials
with the use of
distal protection
systems (SPACE,
EVA-3S, SAPPHIRE)
Exclusion of studies
with asymptomatic
patients (CAVATAS,
Kentucky B,
SAPPHIRE)
30-day risk
of any
stroke
or death,
data
available
from 7
studies
(c2¼ 14.77,
P¼ 0.02)
P¼ 0.14; no sig.
heterogeneity:
c2¼ 11.3,
P¼ 0.14
P¼ 0.02; no sig.
heterogeneity:
c2¼ 11.3,
P¼ 0.08
Exclusion of SPACE:
P¼ 0.02; sig.
heterogeneity:
c2¼ 14.01, P¼ 0.02
P¼ 0.12; sig.
heterogeneity:
c2¼ 9.52, P¼ 0.02
P¼ 0.003; sig.
heterogeneity:
c2¼ 10.4, P¼ 0.03
Exclusion of EVA-3S:
P¼ 0.18; sig. heterogeneity:
c2¼ 11.45, P¼ 0.04
Exclusion of CAVATAS:
P¼ 0.01; sig. heterogeneity:
c2¼ 13.25, P¼ 0.02
Exclusion of SPACE, EVA-3S,
CAVATAS: P¼ 0.11; sig.
Heterogeneity: c2¼ 10.04,
P¼ 0.02safely. In the present meta-analysis, the two completed
and last published series (SPACE, EVA-3S)22,23 have
been added and provide us with additional material.
SPACE22
The SPACE investigators randomized 1183 symptom-
atic patients within 180 days of transient ischaemic at-
tack or moderate stroke (modified Rankin scale of 3)
and reported a 30-day stroke and death rate of 6.34%
for CEA and 6.84% for CAS, which was not statisti-
cally significantly different ( p¼ 0.89).
EVA-3S23
The EVA-3S trial, instead, showed a stroke and death
rate of 3.9% for CEA and 9.6% for CAS by studying
527 symptomatic patients ( p< 0.02). This trial was
stopped before the estimated patient recruitment
was completed. Half the strokes in the patients who
did not have a protection device occurred during
the first postoperative day (N¼ 2) and the other half
evolved on the day of treatment (N¼ 2). Deficient
methods and lack of experience on the part of the
endovascular operator may have undermined the
results of EVA-3S. The results of the EVA-3S trial un-
derscore the need to standardize the training and per-
formance of operators of carotid artery stenting.
The present meta-analysis combined the results of
all seven completed or stopped randomized trials
that compared CAS with CEA between 1998 and 2006.
The results significantly favoured CEA over CAS
with respect to the combined and separate 30-day
risk of death or any stroke, but also death or stroke
at 6 months after the procedure. The risk ofprocedural failure was also greater in the CAS group,
whereas the risk of cranial neuropathy at 30 days was
lower but this is not surprising, considering the na-
ture of the CAS technique and that of CEA.
We did not observe any significant difference be-
tween CAS and CEA when looking at the composite
end point death or stroke at 1 year after the proce-
dure, or ipsilateral intracerebral bleeding at 30 days
after the procedure. CAS may only be beneficial for
a particular group of patients.35 Relative to CEA, the
results of CAS seem favorable only in the setting of
some anatomic conditions that render surgery techni-
cally difficult, such as restenosis after prior CEA, prior
radical neck surgery, and previous radiation therapy
involving the neck and in patients with severe con-
comitant cardiac disease. The findings of this analysis
as compared to that of Coward and colleagues sug-
gest increasing evidence for an advantage of endarter-
ectomy over carotid stenting.
At present carotid-artery stenting should be per-
formed in high volume, specialized centers, where
tailored carotid artery stenting procedures are per-
formed according to the specific characteristics of
the patient and lesion and continiously registered.
Perhaps the safety and efficacy of carotid stenting
will be proved in appropriately selected patients.
Limitations/heterogeneity of included studies
There are a number of limitation in our present ability
to compare endarterectomy and stenting based on this
meta-analysis. Completed and stopped studies were
included in the meta-analysis.
In addition carotid stenting is an evolving proce-
dure being compared with an established treatment
Eur J Vasc Endovasc Surg Vol 34, October 2007
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assessed trials.
However, for most of the outcomes analyzed, in
our meta-analysis the confidence intervals surround-
ing the ORs were more narrow than in the recent
meta-analysis by Coward15 or in the SPACE or EVA-
3S trial. These findings suggest that with larger pa-
tient numbers the advantage of CEA over CAS will
become more significant.
Ongoing studies
Currently, there are two more ongoing trials compar-
ing carotid endovascular treatment with endarte-
rectomy: the International Carotid Stenting Study
(ICSS),24 and the Carotid Revascularization Endarter-
ectomy versus Stenting Trial (CREST),25 adding an-
other 4000 patients to future analyses.
Long-term follow-up results and subgroup analy-
ses are needed to determine whether CAS really is
durable and long-lasting in terms of stroke preven-
tion. This question will be more precisely addressed
when the data from a larger number of patients
with a more extensive follow-up period are available
from the ongoing multicenter prospective random-
ized trials. The results of these studies hopefully
will provide us with evidence to allow surgeons and
other specialists an opportunity to construct valid
guidelines for individual patients.
Summary
There appears to begrowing evidence in favourof a sig-
nificant better primary outcome afterCEA compared to
CAS. As a result, CEA presently remains the ‘‘gold
standard’’ treatment for suitable carotid stenoses.
CAS should only be offered within the ongoing trials
of stenting versus surgery. A general shift in the atti-
tude towards the treatment of carotid disease cannot
be recommended based on the presently available data.
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